应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
PFE 辉瑞
交易中 08-21 11:02:54 EDT
28.37
+0.58
+2.09%
最高
28.43
最低
27.66
成交量
1,101万
今开
27.79
昨收
27.79
日振幅
2.77%
总市值
1,613亿
流通市值
1,601亿
总股本
56.86亿
成交额
3.11亿
换手率
0.20%
流通股本
56.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜辉瑞盘中上涨3.02%，CEO首次自掏腰包买入叠加多重利好提振信心
行情直击 · 08-19 21:46
异动解读｜辉瑞盘中上涨3.02%，CEO首次自掏腰包买入叠加多重利好提振信心
EMA批准辉瑞与Valneva莱姆病疫苗申请，Valneva股价飙升12%，领涨SBF 120指数
美股速递 · 08-14
EMA批准辉瑞与Valneva莱姆病疫苗申请，Valneva股价飙升12%，领涨SBF 120指数
探索院外长期体重管理新模式
上观新闻 · 08-14
探索院外长期体重管理新模式
2026西普会聚焦药店转型：从“卖药”到“健康驿站”的业态重构
智通财经 · 08-13
2026西普会聚焦药店转型：从“卖药”到“健康驿站”的业态重构
康方生物：依沃西联合辉瑞维恩妥尤单抗一线治疗UC国际II/III期研究启动
智通财经 · 08-05
康方生物：依沃西联合辉瑞维恩妥尤单抗一线治疗UC国际II/III期研究启动
辉瑞CEO： 辉瑞已完成业务发展方向的布局押注。公司剩余 60 至 70 亿美元可用于业务拓展，资金的使用将 “极具战略
智通财经 · 08-04
辉瑞CEO： 辉瑞已完成业务发展方向的布局押注。公司剩余 60 至 70 亿美元可用于业务拓展，资金的使用将 “极具战略
辉瑞CEO：公司将在专利到期后维持股息，并恢复股息增长
美股速递 · 08-04
辉瑞CEO：公司将在专利到期后维持股息，并恢复股息增长
辉瑞首席执行官在电话会议上表示，在独占期到期后，公司将维持股息，并恢复股息增长。
智通财经 · 08-04
辉瑞首席执行官在电话会议上表示，在独占期到期后，公司将维持股息，并恢复股息增长。
辉瑞非新冠产品表现强劲，业绩复苏势头更趋稳固
环球市场播报 · 08-04
辉瑞非新冠产品表现强劲，业绩复苏势头更趋稳固
辉瑞（PFE）二季度非GAAP调整后每股收益0.77美元 较市场预期高12.9%
金吾财讯 · 08-04
辉瑞（PFE）二季度非GAAP调整后每股收益0.77美元 较市场预期高12.9%
受艾乐妥等药品强劲表现支撑，辉瑞业绩超预期
环球市场播报 · 08-04
受艾乐妥等药品强劲表现支撑，辉瑞业绩超预期
辉瑞(PFE.US)盈利压力缓解：Q2旧药组合需求旺盛推动2026年营收指引上修，追加25亿美元成本削减
智通财经 · 08-04
辉瑞(PFE.US)盈利压力缓解：Q2旧药组合需求旺盛推动2026年营收指引上修，追加25亿美元成本削减
辉瑞第二季度业绩喜忧参半：肿瘤业务增长，新冠产品下滑
环球市场播报 · 08-04
辉瑞第二季度业绩喜忧参半：肿瘤业务增长，新冠产品下滑
辉瑞：2026年预计因专利及监管独占权到期，收入将面临约11亿美元不利影响——SEC文件披露
美股速递 · 08-04
辉瑞：2026年预计因专利及监管独占权到期，收入将面临约11亿美元不利影响——SEC文件披露
辉瑞股价抹去早盘涨幅，下跌0.5%。
智通财经 · 08-04
辉瑞股价抹去早盘涨幅，下跌0.5%。
辉瑞计划推进Berobenatide III期项目，年内将开展10项针对慢性体重管理与肥胖相关病症的研究
美股速递 · 08-04
辉瑞计划推进Berobenatide III期项目，年内将开展10项针对慢性体重管理与肥胖相关病症的研究
辉瑞：计划今年推进贝罗贝那肽的3期项目，该项目包含10项针对慢性体重管理及肥胖相关病症的研究。
智通财经 · 08-04
辉瑞：计划今年推进贝罗贝那肽的3期项目，该项目包含10项针对慢性体重管理及肥胖相关病症的研究。
辉瑞：AI在降本增效中已见成效，制造业产量扩大——会前发言
美股速递 · 08-04
辉瑞：AI在降本增效中已见成效，制造业产量扩大——会前发言
辉瑞第二季度营收150.3亿美元，超市场预期
老虎资讯综合 · 08-04
辉瑞第二季度营收150.3亿美元，超市场预期
辉瑞目标：2028年底至2033年底，实现风险调整后的高个位数收入复合年增长率——事先准备的发言
美股速递 · 08-04
辉瑞目标：2028年底至2033年底，实现风险调整后的高个位数收入复合年增长率——事先准备的发言
加载更多
公司概况
公司名称：
辉瑞
所属市场：
NYSE
上市日期：
--
主营业务：
辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。
发行价格：
--
{"stockData":{"symbol":"PFE","market":"US","secType":"STK","nameCN":"辉瑞","latestPrice":28.37,"timestamp":1787324573189,"preClose":27.79,"halted":0,"volume":11013817,"delay":0,"changeRate":0.02087081684059021,"floatShares":5644296476,"shares":5685707552,"eps":0.759869,"marketStatus":"交易中","change":0.58,"latestTime":"08-21 11:02:54 EDT","open":27.79,"high":28.425,"low":27.655,"amount":310553304.817717,"amplitude":0.027708,"askPrice":28.38,"askSize":788,"bidPrice":28.37,"bidSize":4644,"shortable":3,"etf":0,"ttmEps":0.759869,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787342400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":-819144000000,"exchange":"NYSE","adjPreClose":27.79,"dividendRate":0.06061,"preHourTrading":{"tag":"盘前","latestPrice":27.7055,"preClose":27.79,"latestTime":"09:29 EDT","volume":98063,"amount":2718982.602448,"timestamp":1787318974997,"change":-0.0845,"changeRate":-0.003041,"amplitude":0.005354},"postHourTrading":{"tag":"盘后","latestPrice":27.7696,"preClose":27.79,"latestTime":"19:59 EDT","volume":1800343,"amount":50031008.817655,"timestamp":1787270398241,"change":-0.0204,"changeRate":-0.000734,"amplitude":0.0038},"volumeRatio":1.310666,"optionData":{"bulkOrders":[{"symbol":"PFE","call":false,"expireDate":1789704000000,"strike":"27.0","timestamp":1787321743488,"price":0.25,"volume":19535,"amount":488375,"type":"+"},{"symbol":"PFE","call":true,"expireDate":1797570000000,"strike":"29.0","timestamp":1787324158910,"price":1.32,"volume":5000,"amount":660000,"type":"+"}]},"impliedVol":0.2529,"impliedVolPercentile":0.3546},"requestUrl":"/m/hq/s/PFE","defaultTab":"news","newsList":[{"id":"1136105151","title":"异动解读｜辉瑞盘中上涨3.02%，CEO首次自掏腰包买入叠加多重利好提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1136105151","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136105151?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:46","pubTimestamp":1787147206,"startTime":"0","endTime":"0","summary":"8月19日，辉瑞盘中上涨3.02%，报28.055美元/股，成交额2.22亿美元。消息面上，Smart Insider于8月18日将辉瑞列为本周精选股票，原因是CEO兼董事长Albert Bourla于8月12日以每股26.34美元首次自购38,000股，耗资约100万美元，持仓增加10%至1,160万美元。此前董事Buckley和Blaylock各购入约100万美元股票，三笔交易被Smart Insider评定为\"自信型\"买入。此外，辉瑞与Valneva合作的莱姆病疫苗近日获EMA受理审评，III期试验有效率超70%，为公司管线增添新增长点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178944800","title":"EMA批准辉瑞与Valneva莱姆病疫苗申请，Valneva股价飙升12%，领涨SBF 120指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1178944800","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178944800?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:08","pubTimestamp":1786691304,"startTime":"0","endTime":"0","summary":"在EMA正式批准辉瑞与Valneva SE联合开发的莱姆病疫苗申请后，市场情绪瞬间被点燃。Valneva的股价应声大涨12%，一举跃升至SBF 120指数涨幅榜的首位。EMA的认可不仅标志着这款疫苗的研发迈出了关键一步，更预示着未来潜在的巨大商业价值。股价的飙升，无疑是对利好消息的最直接回应。Valneva的强势表现，使其在SBF 120指数中脱颖而出，成为当日市场瞩目的焦点。但至少此刻，Valneva与辉瑞正站在舞台中央，享受着来自监管与市场的双重聚光灯。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","IE00BLSP4239.USD","LU1066051498.USD","SG9999003800.SGD","LU0306807586.USD","OZEM","IE00BBT3K403.USD","BK4007","LU1066053197.SGD","LU0456855351.SGD","BK4588","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU1894683264.USD","LU0985481810.HKD","LU0170899867.USD","VALN","SG9999001176.USD","LU0868494617.USD","SG9999011175.SGD","BK4534","LU0058720904.USD","PFE","IE00BLSP4452.SGD","LU1883839398.USD","BK4568","LU0321505439.SGD","BK4581","BK4599","LU0321505868.SGD","LU2596442595.SGD","IE0002270589.USD","LU0225284248.USD","IE00B3T34201.USD","SG9999002232.USD","BK4533","BK4592","SG9999013999.USD","LU0306806265.USD","SG9999001176.SGD","LU0234572021.USD","LU0289739699.SGD","LU1023059063.AUD","IE000M9KFDE8.USD","LU1057294990.SGD","BK4139","SG9999002224.SGD","IE00B19Z3581.USD","LU0225771236.USD","LU0122379950.USD","BK4585","BK4550","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659113912","title":"探索院外长期体重管理新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2659113912","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659113912?lang=zh_cn&edition=full","pubTime":"2026-08-14 14:10","pubTimestamp":1786687830,"startTime":"0","endTime":"0","summary":"体重管理正从单纯关注体重数字，逐渐转向更加注重长期健康的综合管理。肥胖不仅影响体型，还与糖尿病、心血管疾病、脂肪肝等多种健康问题密切相关。对于普通人来说，真正困难的并不是开始减重，而是如何科学长期地管理体重，并将健康习惯坚持下去。体重管理首先需要改变一个认识误区：减重并不等于单纯追求体重下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608143841660149.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608143841660149.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0289739699.SGD","BK4550","LU1894683348.USD","SG9999003800.SGD","LU0225284248.USD","IE00BLSP4239.USD","SG9999001176.SGD","SG9999013999.USD","IE00BLSP4452.SGD","SG9999002232.USD","SG9999001176.USD","LU0456855351.SGD","BK4007","BK4534","BK4585","LU0321505868.SGD","LU1066053197.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU0170899867.USD","BK4533","LU0306806265.USD","LU0868494617.USD","BK4581","PFE","SG9999011175.SGD","SGXZ57979304.SGD","BK4588","LU2596442595.SGD","LU1057294990.SGD","OZEM","SG9999002224.SGD","IE0002270589.USD","BK4592","BK4599","LU1023059063.AUD","LU1066051498.USD","LU1883839398.USD","LU0225771236.USD","LU0306807586.USD","LU0058720904.USD","IE000M9KFDE8.USD","IE00BBT3K403.USD","LU0234572021.USD","IE00B3T34201.USD","BK4568","LU0321505439.SGD","LU1894683264.USD","LU0985481810.HKD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152531","title":"2026西普会聚焦药店转型：从“卖药”到“健康驿站”的业态重构","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659152531?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:35","pubTimestamp":1786624548,"startTime":"0","endTime":"0","summary":"今年1月，商务部等九部委发布《关于促进药品零售高质量发展的意见》，首次在全国层面推动药店从“药品销售终端”升级为”健康驿站”，强化专业服务、健康促进与应急保障三大核心功能。事实上，讨论至最后，与会嘉宾一致认为，健康驿站是行业唯一确定的转型方向，但绝非一蹴而就。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999001176.USD","SG9999013999.USD","SGXZ57979304.SGD","BK0187","IE00BLSP4452.SGD","LU0306807586.USD","301017","IE00BLSP4239.USD","BK4534","BK0239","000423","IE00B19Z3B42.SGD","LU2596442595.SGD","SG9999004220.SGD","002727","SG9999001176.SGD","BK4588","BK0209","LU0122379950.USD","LU0985481810.HKD","BK0012","IE00BBT3K403.USD","LU0321505439.SGD","BK4550","IE000M9KFDE8.USD","BK0183","IE00B19Z3581.USD","LU1057294990.SGD","LU1960683339.HKD","BK4599","BK0175","LU0456855351.SGD","LU1023059063.AUD","SG9999003800.SGD","LU0868494617.USD","OZEM","BK0196","SG9999002224.SGD","BK0164","000538","BK4568","LU1894683264.USD","PFE","SG9999011175.SGD","BK4581","IE00B3T34201.USD","BK4592","LU1066051498.USD","LU1066053197.SGD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544712","title":"康方生物：依沃西联合辉瑞维恩妥尤单抗一线治疗UC国际II/III期研究启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544712","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657544712?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:28","pubTimestamp":1785932889,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348825331.USD","IE00BPRC5H50.USD","LU0321505439.SGD","09926","LU0234572021.USD","IE00B543WZ88.USD","KURE","LU1066051498.USD","LU0321505868.SGD","LU2399975544.HKD","BK4568","LU0456855351.SGD","LU0417516571.SGD","SG9999013999.USD","LU0348767384.USD","IE00BBT3K403.USD","SG9999001176.SGD","BK4592","BK4007","LU0348783233.USD","LU0170899867.USD","LU0348766576.USD","BK4533","LU0540923850.HKD","SG9999001176.USD","LU2596442595.SGD","LU2476274720.SGD","IE00BLSP4239.USD","SG9999011175.SGD","BK1574","IE000M9KFDE8.USD","LU0225284248.USD","LU0289739699.SGD","LU1720050803.USD","BK4585","LU1961090484.USD","BK4581","LU1794554557.SGD","LU0122379950.USD","LU1883839398.USD","LU0058720904.USD","LU0348827113.USD","LU1894683264.USD","SG9999003800.SGD","SG9999002224.SGD","IE00B19Z3581.USD","LU0417516738.SGD","BK4534","LU0634319403.HKD","LU0985481810.HKD","LU0561508036.HKD","SG9999002232.USD","IE00B19Z3B42.SGD","IE00B5MMRT66.SGD","LU0306806265.USD","LU0225771236.USD","LU0417516902.SGD","IE00B3T34201.USD","LU2488822045.USD","LU2476274308.USD","LU0868494617.USD","LU1023059063.AUD","BK4588","IE0002270589.USD","BK1161","PFE","LU0348735423.USD","LU0306807586.USD","BK4550","BK4599","IE00BLSP4452.SGD","LU1066053197.SGD","LU1894683348.USD","SGXZ57979304.SGD","OZEM","LU0348784397.USD","LU1057294990.SGD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656603557","title":"辉瑞CEO： 辉瑞已完成业务发展方向的布局押注。公司剩余 60 至 70 亿美元可用于业务拓展，资金的使用将 “极具战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2656603557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656603557?lang=zh_cn&edition=full","pubTime":"2026-08-04 23:09","pubTimestamp":1785856147,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1066051498.USD","LU1883839398.USD","IE000M9KFDE8.USD","PFE","LU0225284248.USD","LU1894683264.USD","LU1023059063.AUD","BK4588","BK4568","SG9999013999.USD","LU0868494617.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","BK4592","SGXZ57979304.SGD","LU0289739699.SGD","LU0306807586.USD","BK4533","LU0058720904.USD","SG9999001176.SGD","BK4550","BK4581","LU0985481810.HKD","IE00B19Z3581.USD","LU1057294990.SGD","BK4585","LU2596442595.SGD","SG9999003800.SGD","LU0306806265.USD","LU0321505868.SGD","SG9999011175.SGD","IE00BBT3K403.USD","BK4534","IE00BLSP4239.USD","LU0456855351.SGD","LU0321505439.SGD","IE0002270589.USD","LU0122379950.USD","LU0225771236.USD","LU0170899867.USD","BK4007","IE00B3T34201.USD","LU1066053197.SGD","SG9999001176.USD","LU0234572021.USD","OZEM","BK4599","IE00B19Z3B42.SGD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182832883","title":"辉瑞CEO：公司将在专利到期后维持股息，并恢复股息增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1182832883","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182832883?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:59","pubTimestamp":1785855568,"startTime":"0","endTime":"0","summary":"辉瑞首席执行官在业绩电话会议上明确表示，尽管面临专利独占期丧失的挑战，公司仍将坚守股息政策，并在这一特殊时期过后，重新启动股息增长步伐。该声明传递出对股东回报的长期承诺，凸显了管理层对财务稳健性的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0058720904.USD","SG9999002232.USD","BK4585","IE000M9KFDE8.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU2596442595.SGD","SG9999003800.SGD","LU0985481810.HKD","LU1894683264.USD","IE0002270589.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","SG9999001176.SGD","LU1894683348.USD","BK4550","SG9999002224.SGD","LU0225771236.USD","BK4592","LU0321505868.SGD","LU0868494617.USD","LU1066051498.USD","BK4007","LU0122379950.USD","LU1023059063.AUD","LU1066053197.SGD","LU1883839398.USD","LU0289739699.SGD","LU0456855351.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","PFE","SG9999001176.USD","SG9999013999.USD","OZEM","LU0170899867.USD","SG9999011175.SGD","LU0306806265.USD","LU1057294990.SGD","LU0225284248.USD","IE00BBT3K403.USD","LU0321505439.SGD","IE00BLSP4239.USD","BK4534","BK4599","LU0306807586.USD","BK4581","BK4588","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656557318","title":"辉瑞首席执行官在电话会议上表示，在独占期到期后，公司将维持股息，并恢复股息增长。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656557318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656557318?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:58","pubTimestamp":1785855529,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0122379950.USD","LU0306807586.USD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU1894683264.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU1023059063.AUD","LU1894683348.USD","LU0234572021.USD","LU0868494617.USD","LU1883839398.USD","BK4581","BK4568","IE00B19Z3B42.SGD","LU1057294990.SGD","SG9999001176.USD","SG9999003800.SGD","LU2596442595.SGD","LU0170899867.USD","LU0321505868.SGD","BK4592","SGXZ57979304.SGD","IE00B3T34201.USD","BK4550","PFE","IE00BBT3K403.USD","SG9999002224.SGD","SG9999011175.SGD","SG9999001176.SGD","BK4588","BK4534","LU0456855351.SGD","LU0058720904.USD","LU0321505439.SGD","SG9999013999.USD","LU0289739699.SGD","OZEM","IE00BLSP4452.SGD","BK4007","BK4533","BK4599","LU1066051498.USD","LU0225771236.USD","LU0225284248.USD","LU0985481810.HKD","IE00BLSP4239.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656093552","title":"辉瑞非新冠产品表现强劲，业绩复苏势头更趋稳固","url":"https://stock-news.laohu8.com/highlight/detail?id=2656093552","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656093552?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:48","pubTimestamp":1785854880,"startTime":"0","endTime":"0","summary":"辉瑞最新公布的2026年第二季度财报显示，公司复苏势头正变得更加稳固。财报数据显示，辉瑞第二季度营收达到150.3亿美元，同比增长3%，高于分析师预期的144亿美元。这一成绩表明，辉瑞多年来通过收购和内部研发来扩充产品线的战略正在逐步见效。基于第二季度的良好表现，辉瑞将2026年全年营收指引的中值上调了5亿美元，至605亿至625亿美元区间，此前的预期为595亿至625亿美元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-04/doc-inimeknz5611343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1023059063.AUD","LU1894683348.USD","LU1066053197.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4585","LU0321505868.SGD","SGXZ57979304.SGD","LU1894683264.USD","BK4581","IE00B19Z3B42.SGD","IE0002270589.USD","BK4534","SG9999011175.SGD","BK4568","LU1883839398.USD","SG9999001176.SGD","BK4599","LU0321505439.SGD","BK4007","LU0122379950.USD","IE00BBT3K403.USD","BK4550","LU0289739699.SGD","LU1066051498.USD","LU2596442595.SGD","SG9999002232.USD","LU0170899867.USD","LU0868494617.USD","IE00B3T34201.USD","PFE","LU0225284248.USD","LU0234572021.USD","LU0306806265.USD","LU0306807586.USD","OZEM","SG9999003800.SGD","SG9999001176.USD","LU0225771236.USD","LU1057294990.SGD","LU0985481810.HKD","BK4588","IE00BLSP4452.SGD","IE00B19Z3581.USD","SG9999013999.USD","LU0456855351.SGD","SG9999002224.SGD","BK4592","BK4533","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656517445","title":"辉瑞（PFE）二季度非GAAP调整后每股收益0.77美元 较市场预期高12.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656517445","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656517445?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:31","pubTimestamp":1785850316,"startTime":"0","endTime":"0","summary":"金吾财讯 | 全球生物制药巨头辉瑞 披露2026财年第二季度业绩。数据显示，辉瑞二季度实现非GAAP调整后每股收益0.77美元，较分析师预期的0.68美元高出12.9%。公司小幅上调全年营收预期中值至615亿美元，同时维持全年调整后每股收益中值2.90美元不变。从长期经营维度看，辉瑞近五年年化营收增速仅2.1%，但近两年营收年化增速回升至6.4%，有机收入年均增长7.8%，核心业务成为增长主要驱动力。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303409","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SG9999002224.SGD","SG9999003800.SGD","LU0306806265.USD","SG9999011175.SGD","LU1894683264.USD","LU0225771236.USD","LU0985481810.HKD","BK4599","LU0306807586.USD","LU1883839398.USD","LU0234572021.USD","BK4592","SG9999013999.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","IE00BBT3K403.USD","LU2596442595.SGD","IE00BLSP4239.USD","BK4581","BK4533","LU0321505868.SGD","OZEM","SG9999001176.SGD","LU1894683348.USD","BK4585","IE000M9KFDE8.USD","BK4588","IE00B19Z3581.USD","LU1066053197.SGD","LU0289739699.SGD","PFE","SGXZ57979304.SGD","BK4534","IE0002270589.USD","IE00BLSP4452.SGD","LU0868494617.USD","SG9999002232.USD","BK4568","LU0170899867.USD","BK4550","LU0225284248.USD","LU0456855351.SGD","LU1057294990.SGD","LU0321505439.SGD","LU0122379950.USD","SG9999001176.USD","LU0058720904.USD","LU1066051498.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656955923","title":"受艾乐妥等药品强劲表现支撑，辉瑞业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2656955923","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656955923?lang=zh_cn&edition=full","pubTime":"2026-08-04 21:05","pubTimestamp":1785848700,"startTime":"0","endTime":"0","summary":"专题：聚焦美股2026年第二季度财报核心要点辉瑞公布二季度业绩优于市场预期。辉瑞周二发布二季度财报，业绩超出市场预期。辉瑞表示，下调新冠相关产品全年营收预期，从此前约 50 亿美元下调至 40 亿美元。辉瑞还宣布另一项独立降本项目将额外节约 10 亿美元开支，落实周期为 2027 至 2029 年。随着新冠产品收入逐步回落、多款成熟药品面临收入下滑压力，辉瑞加大管线长期投入，近期斥资 100 亿美元收购肥胖领域生物科技企业 Metsera 便是重要布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimekpi1913807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0985481810.HKD","LU2596442595.SGD","OZEM","LU1894683348.USD","BK4534","LU1023059063.AUD","LU0456855351.SGD","LU0058720904.USD","BK4592","SG9999001176.SGD","IE00B19Z3581.USD","LU0122379950.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","BK4599","LU0170899867.USD","LU0306806265.USD","BK4585","BK4550","LU0225284248.USD","IE00BLSP4239.USD","BK4588","LU0289739699.SGD","LU1057294990.SGD","LU1066051498.USD","LU0234572021.USD","BK4533","SG9999001176.USD","LU1883839398.USD","LU1894683264.USD","BK4007","BK4568","LU0225771236.USD","LU0321505439.SGD","SGXZ57979304.SGD","SG9999013999.USD","LU1066053197.SGD","BK4581","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0868494617.USD","SG9999003800.SGD","LU0321505868.SGD","IE00BBT3K403.USD","PFE","LU0306807586.USD","IE00B3T34201.USD","IE0002270589.USD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656598085","title":"辉瑞(PFE.US)盈利压力缓解：Q2旧药组合需求旺盛推动2026年营收指引上修，追加25亿美元成本削减","url":"https://stock-news.laohu8.com/highlight/detail?id=2656598085","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656598085?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:52","pubTimestamp":1785847926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BLSP4239.USD","LU1066051498.USD","SG9999003800.SGD","LU0306807586.USD","OZEM","IE00BBT3K403.USD","BK4007","LU1066053197.SGD","LU0456855351.SGD","BK4588","IE00B19Z3B42.SGD","SGXZ57979304.SGD","LU1894683264.USD","LU0985481810.HKD","LU0170899867.USD","SG9999001176.USD","LU0868494617.USD","SG9999011175.SGD","BK4534","LU0058720904.USD","PFE","IE00BLSP4452.SGD","LU1883839398.USD","BK4568","LU0321505439.SGD","BK4581","BK4599","LU0321505868.SGD","LU2596442595.SGD","IE0002270589.USD","LU0225284248.USD","IE00B3T34201.USD","SG9999002232.USD","BK4533","BK4592","SG9999013999.USD","LU0306806265.USD","SG9999001176.SGD","LU0234572021.USD","LU0289739699.SGD","LU1023059063.AUD","IE000M9KFDE8.USD","LU1057294990.SGD","SG9999002224.SGD","IE00B19Z3581.USD","LU0225771236.USD","LU0122379950.USD","BK4585","BK4550","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656555857","title":"辉瑞第二季度业绩喜忧参半：肿瘤业务增长，新冠产品下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2656555857","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656555857?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:58","pubTimestamp":1785844680,"startTime":"0","endTime":"0","summary":"辉瑞第二季度转为亏损，但营收有所增长，因为其肿瘤业务的增长部分抵消了新冠产品的下滑。其产品艾乐妥、Padcev、Vyndaqel和Lorbrena推动了营收增长，而新冠产品销售额则出现下滑。癌症治疗药物Padcev和Lorbrena均获得了市场份额，分别推动销售额增长23%和37%。其两款新冠产品Paxlovid和Comirnaty的销售额分别下降95%和34%。辉瑞将全年销售指引的低端从此前的595亿至625亿美元上调至605亿至625亿美元。新的展望反映出辉瑞预计其非新冠产品的销售额将比此前预期增加15亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-04/doc-inimeefc5645780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4599","SG9999002232.USD","LU0289739699.SGD","LU0225771236.USD","LU0456855351.SGD","SGXZ57979304.SGD","LU0225284248.USD","SG9999011175.SGD","LU1894683348.USD","BK4581","BK4592","LU0170899867.USD","BK4585","LU2596442595.SGD","LU1883839398.USD","LU1894683264.USD","IE00BLSP4452.SGD","SG9999003800.SGD","LU0321505868.SGD","BK4588","LU0058720904.USD","LU0868494617.USD","IE00BLSP4239.USD","LU1066051498.USD","BK4568","IE00B19Z3581.USD","SG9999013999.USD","LU0234572021.USD","BK4550","BK4533","SG9999001176.SGD","LU0306807586.USD","IE00B3T34201.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1023059063.AUD","LU0306806265.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","OZEM","LU0321505439.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU1057294990.SGD","LU0122379950.USD","LU1066053197.SGD","BK4007","PFE","IE0002270589.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134607849","title":"辉瑞：2026年预计因专利及监管独占权到期，收入将面临约11亿美元不利影响——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1134607849","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134607849?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:22","pubTimestamp":1785842534,"startTime":"0","endTime":"0","summary":"辉瑞公司最新提交的SEC文件显示，展望2026年，该公司如今预计，受专利到期或监管独占权丧失等因素影响，其收入将遭遇大约11亿美元的不利冲击。这一预测标志着企业财务前景的重大调整，凸显了创新药企在专利悬崖面前所承受的持续压力。短期的挑战已然浮现，而长期的产品线布局则显得更为关键。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0306807586.USD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","LU1066053197.SGD","LU1894683264.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU1023059063.AUD","LU1894683348.USD","LU0234572021.USD","LU0868494617.USD","LU1883839398.USD","BK4581","BK4568","IE00B19Z3B42.SGD","LU1057294990.SGD","SG9999001176.USD","SG9999003800.SGD","LU2596442595.SGD","LU0170899867.USD","LU0321505868.SGD","BK4592","SGXZ57979304.SGD","IE00B3T34201.USD","BK4550","PFE","IE00BBT3K403.USD","SG9999002224.SGD","SG9999011175.SGD","SG9999001176.SGD","BK4588","BK4534","LU0456855351.SGD","LU0058720904.USD","LU0321505439.SGD","SG9999013999.USD","LU0289739699.SGD","OZEM","IE00BLSP4452.SGD","BK4007","BK4533","BK4599","LU1066051498.USD","LU0225771236.USD","LU0225284248.USD","LU0985481810.HKD","IE00BLSP4239.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656530783","title":"辉瑞股价抹去早盘涨幅，下跌0.5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656530783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656530783?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:09","pubTimestamp":1785841753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4534","LU1023059063.AUD","IE000M9KFDE8.USD","LU0321505868.SGD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B3T34201.USD","SG9999001176.USD","LU2596442595.SGD","LU0225771236.USD","BK4592","LU1066051498.USD","BK4588","IE00B19Z3B42.SGD","SG9999002224.SGD","LU0225284248.USD","LU0058720904.USD","LU0321505439.SGD","PFE","LU0122379950.USD","BK4568","SGXZ57979304.SGD","LU0289739699.SGD","BK4550","IE0002270589.USD","LU1894683264.USD","BK4599","BK4007","SG9999013999.USD","SG9999002232.USD","SG9999003800.SGD","LU0234572021.USD","LU0306806265.USD","LU1057294990.SGD","LU0170899867.USD","SG9999011175.SGD","OZEM","LU0868494617.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU1894683348.USD","BK4533","SG9999001176.SGD","LU0306807586.USD","LU0456855351.SGD","BK4581","LU0985481810.HKD","IE00B19Z3581.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134381461","title":"辉瑞计划推进Berobenatide III期项目，年内将开展10项针对慢性体重管理与肥胖相关病症的研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1134381461","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134381461?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:59","pubTimestamp":1785841148,"startTime":"0","endTime":"0","summary":"辉瑞宣布，计划进一步推动其药物Berobenatide的III期临床项目。该项目规模庞大，今年内将包含多达10项研究，重点聚焦于慢性体重管理以及各类肥胖相关疾病。这一举措彰显了辉瑞在代谢疾病治疗领域的雄心与布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","IE00BBT3K403.USD","SG9999001176.SGD","BK4592","IE00B19Z3B42.SGD","LU0306806265.USD","IE000M9KFDE8.USD","LU0225284248.USD","LU0225771236.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4585","BK4007","BK4581","LU0868494617.USD","LU1023059063.AUD","LU0321505439.SGD","LU0170899867.USD","LU0122379950.USD","LU1883839398.USD","BK4588","LU0058720904.USD","LU0234572021.USD","IE0002270589.USD","LU1894683264.USD","BK4533","SG9999001176.USD","SG9999003800.SGD","LU1066051498.USD","PFE","SG9999002224.SGD","LU2596442595.SGD","LU0321505868.SGD","IE00B19Z3581.USD","BK4550","LU0306807586.USD","BK4599","IE00BLSP4452.SGD","LU1066053197.SGD","LU1894683348.USD","BK4568","SGXZ57979304.SGD","LU0456855351.SGD","IE00BLSP4239.USD","BK4534","LU0985481810.HKD","OZEM","SG9999013999.USD","LU1057294990.SGD","SG9999011175.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656744537","title":"辉瑞：计划今年推进贝罗贝那肽的3期项目，该项目包含10项针对慢性体重管理及肥胖相关病症的研究。","url":"https://stock-news.laohu8.com/highlight/detail?id=2656744537","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656744537?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:57","pubTimestamp":1785841039,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4568","LU0058720904.USD","SG9999002232.USD","BK4585","IE000M9KFDE8.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU2596442595.SGD","SG9999003800.SGD","LU0985481810.HKD","LU1894683264.USD","IE0002270589.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","SG9999001176.SGD","LU1894683348.USD","BK4550","SG9999002224.SGD","LU0225771236.USD","BK4592","LU0321505868.SGD","LU0868494617.USD","LU1066051498.USD","BK4007","LU0122379950.USD","LU1023059063.AUD","LU1066053197.SGD","LU1883839398.USD","LU0289739699.SGD","LU0456855351.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","PFE","SG9999001176.USD","SG9999013999.USD","OZEM","LU0170899867.USD","SG9999011175.SGD","LU0306806265.USD","LU1057294990.SGD","LU0225284248.USD","IE00BBT3K403.USD","LU0321505439.SGD","IE00BLSP4239.USD","BK4534","BK4599","LU0306807586.USD","BK4581","BK4588","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129760212","title":"辉瑞：AI在降本增效中已见成效，制造业产量扩大——会前发言","url":"https://stock-news.laohu8.com/highlight/detail?id=1129760212","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129760212?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:56","pubTimestamp":1785840963,"startTime":"0","endTime":"0","summary":"辉瑞（Pfizer）已经实实在在地尝到了人工智能带来的甜头——尤其是在削减成本与扩大制造业产量方面。根据其发布的会前发言稿，这家制药巨头强调，AI技术不仅优化了生产流程，还显著提升了产出效率。这种变革并非未来愿景，而是当下正在发生的现实。从降低运营开支到拓宽产量边界，AI正成为辉瑞制造环节的关键推动力。简而言之，人工智能的早期应用成果已经清晰可见，为后续更大规模的部署奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1023059063.AUD","IE00BBT3K403.USD","BK4533","IE00B3T34201.USD","SG9999013999.USD","LU0456855351.SGD","LU2596442595.SGD","SG9999002232.USD","BK4007","SG9999011175.SGD","PFE","IE00BLSP4239.USD","LU0225771236.USD","LU0234572021.USD","LU1894683348.USD","LU1066053197.SGD","SG9999001176.SGD","BK4568","BK4534","LU0225284248.USD","IE0002270589.USD","BK4599","IE00BLSP4452.SGD","LU0321505868.SGD","LU0321505439.SGD","SG9999002224.SGD","OZEM","SG9999001176.USD","LU1894683264.USD","BK4588","BK4585","LU0985481810.HKD","SGXZ57979304.SGD","BK4592","LU1057294990.SGD","LU0289739699.SGD","LU0170899867.USD","LU1883839398.USD","LU0058720904.USD","LU0306806265.USD","LU0122379950.USD","LU1066051498.USD","SG9999003800.SGD","LU0868494617.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4581","BK4550","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176804404","title":"辉瑞第二季度营收150.3亿美元，超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1176804404","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176804404?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:55","pubTimestamp":1785840952,"startTime":"0","endTime":"0","summary":"8月4日，辉瑞第二季度营收150.3亿美元，预估144.1亿美元。第二季度调整后每股收益0.77美元。第二季度ELIQUIS收入 24.3亿美元，预估20.9亿美元。第二季度PREVNAR特许费收入 13.4亿美元。辉瑞预计全年营收605亿美元至625亿美元，市场预估617.6亿美元。辉瑞美股盘前跌超1%。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"辉瑞第二季度营收150.3亿美元，超市场预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165502310","title":"辉瑞目标：2028年底至2033年底，实现风险调整后的高个位数收入复合年增长率——事先准备的发言","url":"https://stock-news.laohu8.com/highlight/detail?id=1165502310","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165502310?lang=zh_cn&edition=full","pubTime":"2026-08-04 18:49","pubTimestamp":1785840591,"startTime":"0","endTime":"0","summary":"辉瑞设定了一项长期财务目标：自2028年底起，直至2033年底，力求达成风险调整后的高个位数收入复合年增长率。这一预期在事先准备的发言稿中明确披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1023059063.AUD","IE00BBT3K403.USD","BK4533","IE00B3T34201.USD","SG9999013999.USD","LU0456855351.SGD","LU2596442595.SGD","SG9999002232.USD","BK4007","SG9999011175.SGD","PFE","IE00BLSP4239.USD","LU0225771236.USD","LU0234572021.USD","LU1894683348.USD","LU1066053197.SGD","SG9999001176.SGD","BK4568","BK4534","LU0225284248.USD","IE0002270589.USD","BK4599","IE00BLSP4452.SGD","LU0321505868.SGD","LU0321505439.SGD","SG9999002224.SGD","OZEM","SG9999001176.USD","LU1894683264.USD","BK4588","BK4585","LU0985481810.HKD","SGXZ57979304.SGD","BK4592","LU1057294990.SGD","LU0289739699.SGD","LU0170899867.USD","LU1883839398.USD","LU0058720904.USD","LU0306806265.USD","LU0122379950.USD","LU1066051498.USD","SG9999003800.SGD","LU0868494617.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4581","BK4550","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pfizer.com","stockEarnings":[{"period":"1week","weight":0.0369},{"period":"1month","weight":0.1143},{"period":"3month","weight":0.073},{"period":"6month","weight":0.0428},{"period":"1year","weight":0.095},{"period":"ytd","weight":0.1161}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1061},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"辉瑞公司于1942年6月2日根据特拉华州法律成立。公司是一家以研究为基础的全球性生物制药公司。公司运用科学和全球资源，通过发现、开发、制造和分销保健产品（包括创新药物和疫苗），为人们带来延长和显著改善其生活的疗法。公司在发达国家和新兴市场开展工作，致力于促进健康、预防、治疗和治愈这个时代最令人恐惧的疾病。公司与医疗保健提供商、政府和当地社区合作，支持并扩大在全球范围内获得可靠、负担得起的医疗保健服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.456522,"avgChangeRate":0.002542},{"month":2,"riseRate":0.456522,"avgChangeRate":-0.005934},{"month":3,"riseRate":0.608696,"avgChangeRate":0.014732},{"month":4,"riseRate":0.574468,"avgChangeRate":0.016819},{"month":5,"riseRate":0.489362,"avgChangeRate":0.007168},{"month":6,"riseRate":0.489362,"avgChangeRate":0.001032},{"month":7,"riseRate":0.489362,"avgChangeRate":0.011937},{"month":8,"riseRate":0.468085,"avgChangeRate":0.002561},{"month":9,"riseRate":0.456522,"avgChangeRate":0.004432},{"month":10,"riseRate":0.630435,"avgChangeRate":0.013042},{"month":11,"riseRate":0.695652,"avgChangeRate":0.028255},{"month":12,"riseRate":0.5,"avgChangeRate":0.008452}],"exchange":"NYSE","name":"辉瑞","nameEN":"Pfizer"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"辉瑞,PFE,辉瑞股票,辉瑞股票老虎,辉瑞股票老虎国际,辉瑞行情,辉瑞股票行情,辉瑞股价,辉瑞股市,辉瑞股票价格,辉瑞股票交易,辉瑞股票购买,辉瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"辉瑞(PFE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供辉瑞(PFE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}